ZURICH/LONDON, Feb 2 (Reuters) -
Swiss drugmaker Novartis declined to comment on Tuesday on market talk it could sell its stake in local rival Roche to help fund its purchase of eyecare company Alcon .
Several traders had cited talk Novartis may sell its stake, worth 33 percent of voting rights in Roche, or some 9.6 billion Swiss francs ($9.1 billion).
Novartis spokesman Eric Althoff said the company does not comment on market rumours.
No hay comentarios:
Publicar un comentario